Open AccessPharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial
Author(s) -
Anthony J Garcia-Prats,
Elin M. Svensson,
Jana Winckler,
Heather R. Draper,
Lee Fairlie,
Louvina E van der Laan,
Masebole Masenya,
H. Simon Schaaf,
Lubbe Wiesner,
Jennifer Norman,
Rob E. Aarnoutse,
Mats O. Karlsson,
Paolo Denti,
Anneke C. Hesseling
Publication year - 2021
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkab336
Subject(s) - medicine , pharmacokinetics , rifampicin , cohort , dosing , adverse effect , population , cohort study , pharmacology , tuberculosis , environmental health , pathology
Rifampicin doses of 40 mg/kg in adults are safe and well tolerated, may shorten anti-TB treatment and improve outcomes, but have not been evaluated in children.